サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ペラグラ治療の世界市場（2022年～2029年）
市場調査レポート
商品コード
1078236

ペラグラ治療の世界市場（2022年～2029年）

Global Pellagra Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペラグラ治療の世界市場（2022年～2029年）
出版日: 2022年05月25日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のペラグラ治療市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および課題、顧客情勢、薬剤・タイプ・流通チャネル・地域別の分析、さら企業プロファイルなどを提供しています。

目次

第1章 ペラグラ治療市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 ペラグラ治療市場：市場の定義と概要

第3章 ペラグラ治療市場：エグゼクティブサマリー

  • 薬剤別の市場内訳
  • タイプ別の市場内訳
  • 流通チャネル別の市場内訳
  • 地域別の市場内訳

第4章 ペラグラ治療市場：市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 ペラグラ治療市場：業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ

第6章 ペラグラ治療市場：COVID-19分析

  • 市場へのCOVID-19の分析
    • COVID-19前の市場シナリオ
    • 現在のCOVID-19市場シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19における価格変動
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 ペラグラ治療市場：薬剤別

  • イントロダクション
  • 薬剤別の市場規模分析、および前年比成長分析
  • 薬剤別の市場魅力指数
    • ニコチン
    • ナイアシンアミド

第8章 ペラグラ治療市場：タイプ別

  • イントロダクション
  • タイプ別の市場規模分析、および前年比成長分析
  • タイプ別の市場魅力指数
    • 一次ペラグラ
    • 二次ペラグラ

第9章 ペラグラ治療市場：流通チャネル別

  • イントロダクション
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場魅力指数
  • 病院薬局
    • イントロダクション
    • 市場規模分析（2020年～2029年、および2021年～2029年）
  • 小売薬局
  • その他

第10章 ペラグラ治療市場：地域別

  • イントロダクション
    • 地域別の市場規模分析（2020年～2029年、および2021年～2029年）
    • 地域別の市場魅力指数
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤別の市場規模分析、および前年比成長分析
    • タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤別の市場規模分析、および前年比成長分析
    • タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤別の市場規模分析、および前年比成長分析
    • タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤別の市場規模分析、および前年比成長分析
    • タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤別の市場規模分析、および前年比成長分析
    • タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析

第11章 ペラグラ治療市場：競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク

第12章 ペラグラ治療市場：企業プロファイル概要

  • Western Drugs Ltd.
    • 企業概要
    • 製品ポートフォリオ・種類
    • 主要ハイライト
    • 財務概要
  • DSM
  • Merck KGaA
  • Foodchem International Corporation
  • Jubilant Life Sciences Limited
  • Lasons
  • Bazayan & Co
  • Resonance Specialties Limited
  • Veer-Chemie

第13章 ペラグラ治療市場：DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH5151

Market Overview

The global pellagra treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pellagra is a disease caused by a dietary deficiency in niacin (one of the B complex vitamins) or tryptophan (an amino acid).

Market Dynamics

The factors influencing the global pellagra treatment market are the increasing research and development and the increasing prevalence of pellagra.

The increasing research and development is expected to drive the market growth in the forecast period

Pellagra is a disease caused by a dietary deficiency in niacin (one of the B complex vitamins) or tryptophan (an amino acid). The triad of dermatitis, diarrhea, and dementia are the classic clinical features of pellagra, though most people do not have all three. Headache, irritability, poor concentration, apathy and confusion, vertigo, myoclonus, tremor, rigidity, weakness, dysphagia, seizures, and various psychiatric symptoms are all examples of neurologic abnormalities. Patients become disoriented, confused, and delirious as pellagra progresses, then stuporous and comatose, and finally die.

Pellagra can occur in people with Crohn's disease due to niacin deficiency caused by malabsorption and tryptophan wastage combined with increased 5-hydroxyindoleacetic acid excretion in the urine. Pellagra has been linked to infectious colitis and malabsorption caused by intestinal bacterial overgrowth. Niacin, also known as vitamin B3, is a generic name for two compounds: nicotinamide and nicotinic acid. It is required for carbohydrate, fat, protein, alcohol metabolism, drug and reactive oxygen species detoxification, cell signaling, and DNA repair. Niacin-rich foods include tuna fish, chicken, beef, peanuts, mushroom, avocado, and green peas, with recommended daily intakes of 14 mg. At the same time, HIV patients are expected to have higher niacin requirements. Moreover, the WHO recommends taking at least 300 mg nicotinamide in an oral divided daily dose for 3-4 weeks to treat pellagra. Niacin-induced flushing necessitates the use of nicotinamide. General malnutrition and cachexia may necessitate the use of additional dietary supplements.

Limitations associated with pellagra treatment are expected to hamper the market growth

Niacin is probably safe for most people when taken by mouth. Niacin can cause a flushing reaction, a common minor side effect. Side effects include burning, tingling, itching, redness of the face, arms, chest, and headaches. Starting with small doses of niacin and taking 325 mg of aspirin before each dose of niacin can help to reduce the flushing reaction. This reaction usually subsides as the body adjusts to the medication. Alcohol can exacerbate the flushing reaction. When taking niacin, one should stay away from large amounts of alcohol. Concerns have been raised about the risk of stroke in people who take niacin. According to one large study, people who took high doses of niacin had a two-fold higher risk of stroke than those who did not take niacin.

COVID-19 Impact Analysis

Countries worldwide went into lockdown early in the COVID-19 pandemic, shutting down or reducing transport within and between them. This impacted medicine manufacturing, supply, and distribution, causing global medicines supply chain bottlenecks. Some medicines used in COVID-19 patients have also seen an increase in demand. For instance, niacin is a component of NAD and NADP, important during chronic systemic inflammation. Increased levels of NAD+ are required to treat a wide range of pathophysiological conditions because it acts as a coenzyme in various metabolic pathways. NAD+ is produced in the early stages of inflammation and has immunomodulatory properties, lowering pro-inflammatory cytokines such as IL-1, IL-6, and TNF-.According to new research, targeting IL-6 may help control the inflammatory storm in COVID-19 patients. Niacin could be used as an adjunct treatment for COVID-19 patients because of its lung-protective and immune-strengthening properties. Hence, covid-19 is expected to positively impact the market with the rise in demand for niacin.

Segment Analysis

Primary pellagra is expected to dominate the market growth

Diets low in niacin or tryptophan cause primary pellagra. Because tryptophan is converted to niacin in the body, a lack of it can result in a niacin deficiency. Primary pellagra is common in developing countries where corn (maize) is a major food source or aftermath of long-term disasters such as famine or war. Corn is high in niacin, but it is locked up in a bound form that can only be accessed with alkaline solutions, and corn proteins are low in tryptophan. Pellagra is still endemic in India, China, and parts of Africa.

Dietary and lifestyle changes and a niacin or nicotinamide supplement treat primary pellagra. Nicotinamide is another form of Vitamin B3 used to treat pellagra in its early stages. When a disease is detected early on, it is possible to recover completely within a few days of starting treatment. On the other hand, skin improvement may take some time (usually a few months). When pellagra is left untreated, it can lead to death in as little as 4-5 years.

Geographical Analysis

North America region is expected to hold the largest market share in the global pellagra treatment market

The growing prevalence of pellagra and increasing research and development in this region is expected to drive the market growth.

Pellagra (a niacin deficiency disease) claimed more than 100,000 lives in the United States alone, affecting more than 3 million people. Pellagra reached epidemic proportions in the American South in the early 1900s. Pellagra infected over 3 million Americans during that time, resulting in over 100,000 deaths, but the epidemic ended after dietary niacin fortification. Hence, with pellagra's increasing prevalence, the demand for its treatment increased. And is expected to boost the market growth in North America region.

Competitive Landscape

With mergers, acquisitions, and product launches, the global pellagra treatment market is moderately competitive. Some of the key players in the market are DSM, Merck KGaA, Foodchem International Corporation, Jubilant Life Sciences Limited, Western Drugs Ltd., Lasons, Bazayan & Co, Resonance Specialties Limited, Veer-Chemie

Western Drugs Ltd.

Overview: Western Drugs Ltd. is a leading manufacturer of Niacin (Nicotinic Acid) and Niacinamide. The company was founded in 1989 and is headquartered in India.

Product Portfolio: Vitamin B3 Niacin (Nicotinic Acid) is a nutrient additive used in food, feed, and pharmaceutical/nutritional products. It is an essential B complex vitamin, also known as Vitamin B3, with various uses. It is available in powder and granular form.

Why Purchase the Report?

Visualize the composition of the global pellagra treatment market segmentation by drug, type, and distribution channel, highlighting the key commercial assets and players.

identify commercial opportunities in global pellagra treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global pellagra treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pellagra treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Pellagra Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Pellagra Treatment Market- Market Definition and Overview

3. Pellagra Treatment Market- Executive Summary

  • 3.1. Market Snippet By Drug
  • 3.2. Market Snippet By Type
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet By Region

4. Pellagra Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with pellagra treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Pellagra Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Pellagra Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Pellagra Treatment Market- By Drug

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
  • 7.3. Market Attractiveness Index, By Drug
    • 7.3.1. Niacin
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Niacinamide

8. Pellagra Treatment Market-By Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 8.3. Market Attractiveness Index, By Type
    • 8.3.1. Primary Pellagra
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Secondary Pellagra

9. Pellagra Treatment Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Other

10. Pellagra Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Pellagra Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Pellagra Treatment Market- Company Profiles

  • 12.1. Western Drugs Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. DSM
  • 12.3. Merck KGaA
  • 12.4. Foodchem International Corporation
  • 12.5. Jubilant Life Sciences Limited
  • 12.6. Lasons
  • 12.7. Bazayan & Co
  • 12.8. Resonance Specialties Limited
  • 12.9. Veer-Chemie

LIST NOT EXHAUSTIVE

13. Pellagra Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us